<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074230</url>
  </required_header>
  <id_info>
    <org_study_id>ERLANGEN-DERMA-ER-DC-06</org_study_id>
    <secondary_id>CDR0000343699</secondary_id>
    <secondary_id>EU-20317</secondary_id>
    <nct_id>NCT00074230</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma</brief_title>
  <official_title>Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's dendritic cells and antigens may make the body build&#xD;
      an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy using autologous&#xD;
      dendritic cells with antigens in treating patients who have stage IV cutaneous melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and tolerability of vaccination with autologous monocyte-derived&#xD;
           dendritic cells (DC) transfected with RNAs encoding Melan-A, MAGE-3, and survivin&#xD;
           antigens in patients with stage IV cutaneous melanoma.&#xD;
&#xD;
        -  Determine whether tumor antigen-specific T-cell responses are induced in patients&#xD;
           treated with this vaccine.&#xD;
&#xD;
        -  Determine whether simultaneous loading of DC with keyhole limpet hemocyanin (KLH)&#xD;
           significantly enhances induction of the Melan-A, MAGE-3, and survivin antigens in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine clinical antitumor activity (e.g., objective tumor response, time to tumor&#xD;
           progression, progression-free interval, and overall survival) in patients treated with&#xD;
           this vaccine.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized study.&#xD;
&#xD;
        -  Phase I: Beginning 9-11 days before vaccination, patients undergo leukapheresis for&#xD;
           collection of peripheral blood mononuclear cells (PBMCs). PBMCs are processed for the&#xD;
           generation of dendritic cells (DC) to be used for vaccinations. PBMCs are transfected&#xD;
           with RNAs encoding for Melan-A, MAGE-3, and survivin antigens. DC are pulsed with&#xD;
           keyhole limpet hemocyanin (KLH) for some patients.&#xD;
&#xD;
      Patients receive antigen-pulsed (with or without KLH) DC vaccination subcutaneously (SC) on&#xD;
      days 1, 15, 43, and 71 in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients with stable or responding disease may proceed to the phase II portion of the study.&#xD;
&#xD;
        -  Phase II: Patients undergo leukapheresis as in phase I on days 102, 354, and 690.&#xD;
           Patients receive up to 6 additional booster vaccinations SC as in phase I on days 127,&#xD;
           185, 269, 356, 521, and 692.&#xD;
&#xD;
      Patients are followed for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-30 patients will be accrued for this study within 6-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability at every visit</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival as assessed by clinical staging (CT scan, positron emission tomography [PET]) every 3 months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression as assessed by clinical staging (CT scan, PET) every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response as assessed by clinical staging (CT scan, PET) every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response as assessed by clinical staging (CT scan, PET) every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of antigen-specific immune responses as assessed by elispot and tetramer staining at every visit</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">82</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin</intervention_name>
    <description>Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous* melanoma&#xD;
&#xD;
               -  Stage IV&#xD;
&#xD;
          -  Incurable by surgical resection&#xD;
&#xD;
          -  Progressive disease after at least 1 standard chemotherapy or chemoimmunotherapy&#xD;
             regimen (e.g., dacarbazine or cisplatin monotherapy)&#xD;
&#xD;
          -  Unidimensionally or bidimensionally measurable disease by physical examination (e.g.,&#xD;
             cutaneous metastases) and/or noninvasive radiological procedures&#xD;
&#xD;
          -  No active CNS metastases by CT scan or MRI&#xD;
&#xD;
               -  Previously treated (e.g., excision of a single metastasis) CNS metastases are&#xD;
                  allowed provided there are no signs of active CNS metastases NOTE: *Metastatic&#xD;
                  melanoma with unidentified primary tumor allowed provided an ocular melanoma can&#xD;
                  be definitely excluded and origin from the skin is likely&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 2,500/mm^3&#xD;
&#xD;
          -  Neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 700/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  No evidence of hepatitis B or C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No respiratory disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV-1 and HIV-2 negative&#xD;
&#xD;
          -  HTLV-1 negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
          -  No active autoimmune disease (e.g., lupus erythematosus, autoimmune thyroiditis or&#xD;
             uveitis, multiple sclerosis, or inflammatory bowel disease)&#xD;
&#xD;
               -  Vitiligo allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 4 weeks&#xD;
             after study participation&#xD;
&#xD;
          -  Stable medical condition&#xD;
&#xD;
          -  No other major serious illness&#xD;
&#xD;
          -  No contraindication to leukapheresis&#xD;
&#xD;
          -  No organic brain syndrome or significant psychiatric abnormality that would preclude&#xD;
             study participation or follow-up&#xD;
&#xD;
          -  No other active malignant neoplasm&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No other concurrent immunotherapy during and for 2 weeks after study participation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas [e.g.,&#xD;
             fotemustine])&#xD;
&#xD;
          -  No concurrent chemotherapy during and for 2 weeks after study participation&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids during and for 2 weeks after study participation&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  Concurrent palliative radiotherapy to selected metastases (e.g., due to pain or local&#xD;
             complications such as compression) is allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
          -  Concurrent surgical therapy to selected metastases (e.g., due to pain or local&#xD;
             complications such as compression) is allowed&#xD;
&#xD;
               -  Selected accessible metastases may be removed for tumor infiltrating lymphocyte&#xD;
                  assay or other immunomonitoring investigations (e.g., expression of tumor&#xD;
                  antigens and HLA molecules)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drug or paramedical substance during and for 2&#xD;
             weeks after study participation&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  Concurrent palliative medication allowed (e.g., acetaminophen, indomethacin, or&#xD;
             opiates)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. univ. Beatrice Schuler-Thurner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BIRC5 protein, human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

